Search
forLearn
5 / 801 resultslearn octapeptide-2
learn ceramide 2
learn Ethynylestradiol
learn plant sterol complex
Research
5 / 27 resultsresearch Sesn2/AMPK/mTOR signaling mediates balance between survival and apoptosis in sensory hair cells under stress
Sesn2 protects inner ear hair cells from damage by regulating certain cell survival pathways.
research October 27, 1978
A document listed serious side effects from various drugs, including deaths and diseases, emphasizing the importance of being aware of drug side effects.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Exosomes Secreted from Adipose-Derived Stem Cells Are a Potential Treatment Agent for Immune-Mediated Alopecia
Exosomes from fat-derived stem cells can potentially improve hair growth and could be a new treatment for immune-related hair loss.
research Linking diet to acne metabolomics, inflammation, and comedogenesis: an update
Eating less sugar, milk, and saturated fats and more vegetables and fish may help treat and prevent acne.
Community Join
5 / 1000+ resultscommunity Trestolone (MENT) as a nuclear treatment
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.